| A Study Evaluating the Long-term Safety of VX-445 Combination Therapy (NCT04043806) | Vertex Pharmaceuticals Incorporated | 2019-08-09 |
| A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis (NCT03912233) | Vertex Pharmaceuticals Incorporated | 2019-04-30 |
| A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis (NCT03911713) | Vertex Pharmaceuticals Incorporated | 2019-04-17 |
| A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy (NCT03764072) | Vertex Pharmaceuticals Incorporated | 2018-12-12 |
| A Safety and Efficacy Study Evaluating CTX001 in Subjects With Severe Sickle Cell Disease (NCT03745287) | Vertex Pharmaceuticals Incorporated | 2018-11-27 |
| Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age (NCT03691779) | Vertex Pharmaceuticals Incorporated | 2018-10-02 |
| A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia (NCT03655678) | Vertex Pharmaceuticals Incorporated | 2018-09-14 |
| Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del (NCT03601637) | Vertex Pharmaceuticals Incorporated | 2018-09-07 |
| A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del (NCT03625466) | Vertex Pharmaceuticals Incorporated | 2018-08-10 |
| Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age (NCT03633526) | Vertex Pharmaceuticals Incorporated | 2018-08-03 |
| A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F) (NCT03525548) | Vertex Pharmaceuticals Incorporated | 2018-08-03 |
| A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy (NCT03447262) | Vertex Pharmaceuticals Incorporated | 2018-07-13 |
| A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) (NCT03525444) | Vertex Pharmaceuticals Incorporated | 2018-06-15 |
| A Study to Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis (NCT03559062) | Vertex Pharmaceuticals Incorporated | 2018-05-17 |
| A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F) (NCT03460990) | Vertex Pharmaceuticals Incorporated | 2018-05-01 |
| A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation (NCT03537651) | Vertex Pharmaceuticals Incorporated | 2018-04-25 |
| Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis (NCT03768089) | Vertex Pharmaceuticals Incorporated | 2018-03-20 |
| A Phase 3 Study of VX-659 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF) (NCT03447249) | Vertex Pharmaceuticals Incorporated | 2018-03-07 |
| A Study to Evaluate the Efficacy and Safety of VX-150 in Treating Subjects With Pain Caused by Small Fiber Neuropathy (NCT03304522) | Vertex Pharmaceuticals Incorporated | 2017-09-20 |